Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?  by Pappas, Sam G. et al.
ORIGINAL ARTICLE
Staging chest computed tomography and positron emission
tomography in patients with pancreatic adenocarcinoma:
utility or futility?
Sam G. Pappas1, Kathleen K. Christians2, Parag P. Tolat4, Alan P. Mautz4, Alysandra Lal2, Lisa McElroy2,
T. Clark Gamblin2, Kiran K. Turaga2, Susan Tsai2, Beth Erickson3, Paul Ritch3 & Douglas B. Evans2
1Department of Surgery, Loyola University Medical Center, Maywood, IL, USA and Departments of 2Surgery, 3Medical and Radiation Oncology, and
4Radiology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA
Abstract
Objectives: This study was conducted to determine if routine staging chest computed tomography (CT)
or positron emission tomography (PET) scanning alters the clinical management of patients with newly
diagnosed pancreatic adenocarcinoma.
Methods: All new pancreas cancers seen in medical oncology, radiation oncology and surgery from 1
June 2008 to 20 June 2010 were retrospectively reviewed. Patients with metastatic disease on chest CT
or PET, that had been unsuspected on initial imaging, were identified.
Results: Pancreatic adenocarcinoma was present in 247 consecutive patients. Abdominal CT demon-
strated metastases in 108 (44%) and localized disease in 139 (56%) patients. Chest CT and PET were not
performed in 15 (11%) of these 139 patients. In the remaining 124 patients, CT imaging suggested
resectable disease in 46, borderline resectable disease in 52 and locally advanced disease in 26 patients.
Chest CT demonstrated an unsuspected lymphoma in one patient with borderline resectable disease and
PET identified extrapancreatic disease in two patients with locally advanced disease. Chest CT and PET
added no information in 121 (98%) of the 124 patients.
Conclusions: The addition of chest CT and PET to high-quality abdominal CT is of little clinical utility;
additional sites of metastasis are rarely found. As the quality of abdominal imaging declines, the yield from
other imaging modalities will increase. Dedicated pancreas-specific abdominal CT remains the corner-
stone of initial staging in suspected or biopsy-proven pancreatic cancer.
Received 17 September 2012; accepted 18 January 2013
Correspondence
Sam G. Pappas, Department of Surgery, 2160 South First Avenue, Maywood, IL 60153, USA. Tel:
+ 1 7083273430. Fax: + 1 7083273565. E-mail: sgpappas@lumc.edu
Introduction
Current National Comprehensive Cancer Network (NCCN)
guidelines for staging patients with pancreatic adenocarcinoma
have been revised to include a dedicated chest computed tomog-
raphy (CT) scan to evaluate for lung metastases.1,2 Pulmonary
evaluation is important because the presence of pulmonary
metastases will influence subsequent treatment recommenda-
tions, affect clinical trial eligibility, and have obvious implications
for surgery directed at the primary tumour. For example, patients
with resectable pancreatic adenocarcinoma (resectable primary
tumour), in whom indeterminate lung lesions are found on
imaging, are classified as borderline resectable according to the
Katz classification (type B) in view of concern for distant metas-
tases.3 In such patients, resection of the primary tumour is
usually not performed as the first treatment modality. Type B
patients are generally offered neoadjuvant chemotherapy, with or
without chemoradiation.4–6 This strategy allows for the lung
lesions to be further clarified over time, during which systemic
therapy is provided to treat both local and potentially distant
disease.
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Accurate staging tools are needed to improve preoperative
patient selection and offer stage-appropriate therapies to patients
with newly diagnosed cancer of the pancreas. Computed tomog-
raphy of the chest and positron emission tomography (PET) can
potentially influence the management of patients with resectable
pancreas cancer. However, there are very few data to support the
routine use of chest CT or PET scanning, or the combination of
both, in these patients. Chest CT scanning has been shown to be
more sensitive and specific than chest X-ray in identifying lung
cancer and in identifying lung metastases in patients with peri-
ampullary tumours.7,8 Lung metastases are often a later finding in
patients who have already developed liver metastases, peritoneal
carcinomatosis or malignant ascites. Many practices now incor-
porate CT and PET or combined CT/PET within the staging
workup.9–11 However, there is no firm consensus on the precise
roles of these and additional staging studies in patients with newly
diagnosed pancreatic cancer.
The present group hypothesized that staging chest CT and PET
fail to identify new sites of disease beyond those seen in abdominal
CT and chest X-ray in patients with newly diagnosed pancreatic
cancer. If lung metastases were found in patients with disease that
was otherwise considered to be resectable according to conven-
tional imaging methods, such patients would not be considered
for surgery. The aim of this study was therefore to determine if
routine staging chest CT or PET scanning alters the clinical man-
agement of patients presenting with newly diagnosed pancreatic
adenocarcinoma.
Materials and methods
Subsequent to institutional review board approval, all new pan-
creatic cancer patients seen in the Departments of Medical Oncol-
ogy, Radiation Oncology and Surgery at the Medical College of
Wisconsin from 1 June 2008 to 30 June 2010 were retrospectively
reviewed. Pancreas protocol CT (PPCT), chest X-ray, chest CT
and PET were all re-reviewed by three of the present authors (SGP,
APM, PPT). A pulmonary nodule scoring system designed to
allow findings on these imaging studies to be objectively reviewed
and compared was developed (Table 1). Although no specific cri-
teria or definitions have been described for the evaluation of pul-
monary metastasis in chest CT, the nodule scoring system was
used to categorize the initial imaging studies of patients in the
present series. In addition, PET scans were reviewed and qualita-
tively scored as positive or negative for additional suspicious find-
ings in comparison with chest CT scans.
All patient examinations were reviewed with particular atten-
tion to the presence of suspicious pulmonary nodules. The major-
ity of staging studies had been performed at the present institution;
however, a subset of patients had already undergone imaging prior
to evaluation at this institution. In this scenario, these studies were
added to the present institution’s imaging archive and were evalu-
ated.Outside examinationswere includedonlywhendeemeddiag-
nostic by the interpreting radiologists and were excluded if they
presented artefact or technical inadequacy. Examinations were
reviewed retrospectively by two experienced radiologists. Exami-
nation findings were categorized accordingly by consensus.A third
radiologist reviewed any cases in which disagreement occurred.
Patients with newly diagnosed pancreas cancer were clinically
and radiographically staged based on CT imaging findings and
clinical performance status.5,6 Resectable disease (stage I or II) was
defined, based on CT images, as a normal tissue plane between the
tumour and adjacent arterial structures and a patent superior
mesenteric vein–portal vein (SMV–PV) confluence. Patients with
borderline resectable disease represented three different subtypes
as previously described (Katz types A, B and C).3 Type A patients
had tumour abutment (180 °) of the superior mesenteric or
coeliac arteries and an occluded SMV–PV confluence with an
adequate segment of vein above and below the area of tumour
involvement to allow for venous resection and reconstruction.
Type B and C patients included those with questionable metastatic
disease and marginal performance status, respectively. Locally
advanced (stage III) tumours were considered as those that exhib-
ited tumour encasement (>180 °) of the adjacent arteries or an
occluded SMV–PV confluence with no technical option for
venous reconstruction. Patients with metastatic disease (stage IV)
at presentation had radiographic evidence of liver, lung, perito-
neal or other sites of distant metastases.1
Patients with non-pancreatic periampullary tumours, and
those with pancreatic tumours that were not adenocarcinomas







2 Stable pulmonary nodules for 2 years
3 Homogeneous calcified nodules
4 Opacities not related to malignancy (i.e.
atelectasis, congestive heart failure,
pulmonary scarring/fibrosis,
emphysema)
1 Indeterminate 1 Solitary pulmonary nodules <5 mm
2 Pulmonary nodules <5 mm with
short-interval stability (<2 years)
3 Pleural effusion, pleural plaques, and
infectious/inflammatory ground glass
and tree-in-bud opacities
2 Suspicious 1 Solitary pulmonary nodule of >5 mm
2 Multiple pulmonary nodules
3 Definite
metastasis(es)
1 Multiple, bilateral, peripheral, lower lobe
pulmonary nodules of varying size
(haematogenous spread)
2 Diffuse nodular interstitial thickening
(lymphangitic spread)
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(i.e. intraductal papillary mucinous neoplasms, neuroendocrine
tumours) were excluded.
Results
Cytologic or histologic confirmation of pancreatic adenocarci-
noma was present in 247 consecutive patients. Abdominal CT
demonstrated metastatic disease in 108 (44%) patients and local-
ized disease in 139 (56%) (Fig. 1). In 15 (11%) of these 139
patients, chest CT or PET were not performed. In the remaining
124 patients, CT imaging suggested resectable disease in 46, bor-
derline resectable disease in 52 and locally advanced disease in 26
patients. Chest CT demonstrated an unsuspected mediastinal
mass (unrelated to pancreas cancer) in one patient with border-
line resectable disease and PET identified extrapancreatic disease
in two patients with locally advanced disease. Chest CT and PET
added no new information in 121 (98%) of the 124 patients.
In the 46 patients with resectable disease, chest CT and PET
scans were performed and were available for comparison with
pancreas CT and chest X-ray. In 43 (93%) of the 46 patients, chest
CT and PET provided no additional information.New findings on
chest CT and/or PET emerged for three patients. In two patients,
the chest CT nodule score was suspicious for metastatic disease;
the PET scan was read as negative in both patients. One patient
underwent lung biopsy which demonstrated a hamartoma and the
other patient submitted to a supraclavicular lymph node biopsy,
which was also negative for malignancy. In one resectable patient,
chest CT findings were indeterminate and PET was negative. This
patient underwent a surgery-first approach and did not receive
neoadjuvant therapy. The same patient progressed to develop liver
and lung metastases within 3 months of surgery.
In the 52 patients with borderline resectable disease, chest CT
and PET scans were performed and were available for comparison
with pancreas CT and chest X-ray. In 46 (88%) of these 52
patients, the addition of chest CT and PET scanning to conven-
tional staging studies added no further information. In four
patients chest CT showed suspicious nodules. All patients had
negative PET scans and all patients went on to submit to pancre-
atic cancer resection without significant interval change on repeat
imaging prior to surgery. In one patient an obvious mass was
detected on chest CT and PET. This patient had a concomitant
primary lymphoma, was treated for this and subsequently under-
went resection of the primary pancreatic cancer.
In the 26 patients with locally advanced disease, chest CT and
PET scans were performed and were available for comparison
with CT of the pancreas and chest X-ray. In 24 (92%) of these
patients, chest CT and PET demonstrated no additional findings.
In two patients, PET scanning after initial systemic therapy iden-
tified disease not seen on abdomen CT or chest X-ray; this
involved metastatic disease to the adrenal gland in one patient and
to the supraclavicular fossa in the other. Both patients had normal
or indeterminate findings on chest CT. The majority of patients
Figure 1 Findings in 247 consecutive patients with pancreas cancers at the Medical College of Wisconsin. CT, computed tomography;
PET, positron emission tomography
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(108 of 247, 44%) had metastases at presentation and only four
patients presented with lung-only metastases. In all four patients,
the lung metastases were visible and suspicious on review of the
lower lung fields of the pancreas CT. Eighty of the 108 (74%)
patients with metastatic disease were found to be unresectable as
a result of liver metastases. The remaining 24 were unresectable
for other reasons (ascites, peritoneal carcinomatosis, etc.)
Discussion
Staging chest CT or PET scans rarely altered the clinical manage-
ment strategy for patients presenting with newly diagnosed pan-
creatic adenocarcinoma. In fact, there were no instances in the
resectable and borderline resectable categories in which staging
chest CT or PET identified occult metastatic disease that pre-
cluded surgery. The one resectable patient in whom chest CT
showed indeterminate findings underwent a surgery-first
approach and suffered disease progression after surgery in the
liver and lung. Prior imaging was not available for this patient,
who was found to have multiple bilateral small (<5 mm) pulmo-
nary nodules that would have warranted further imaging accord-
ing to the nodule scoring system used in this study. The two
resectable patients in whom chest CT findings were suspicious
both had negative PET scans and neither progressed after receiv-
ing preoperative neoadjuvant therapy. These patients were felt to
represent false positive chest CT results on retrospective review.
The precise role of additional imaging studies in patients with
newly diagnosed cancer of the pancreas is not known. Although
the use of PET scanning alone or in combination with CT scan-
ning as a diagnostic procedure may seem reasonable, studies have
failed to demonstrate that these techniques improve the accuracy
of radiographic staging or alter recommendations for the
sequencing of therapy.8 However, high-quality PPCT, as per-
formed in this series, may not be available at all institutions. The
roles of additional or complementary staging studies may vary
based on the quality of CT or magnetic resonance imaging.
Although staging chest CT and PET scans are included within the
staging workup of pancreas cancer patients enrolled in clinical
trials, the incremental benefit of this practice for off-protocol
patients is not apparent based on the present review.
None of the patients with stage I or stage II pancreatic head
carcinoma demonstrated suspicious findings on chest CT; the
additional chest imaging did not change clinical management.
Neither did chest CT or PET change clinical management in
patients with stage IV disease. Patients with locally advanced stage
III disease are not considered for surgery and are usually treated
with systemic therapy prior to consideration for chemoradiation.
In such patients, the finding of an additional site of possible
metastatic disease in the lungs or bone may affect eligibility for
clinical trials, but would not affect treatment sequencing if sys-
temic therapy is delivered prior to consideration of locoregional
chemoradiation. Most patients with localized (resectable or bor-
derline resectable) pancreas cancer harbour radiographically
occult metastatic disease even if this is not apparent on imaging
studies and therein lies the rationale for the provision of com-
bined modality therapy prior to consideration for surgery.4 This
group therefore favours neoadjuvant therapy or chemoradiation,
even in patients with resectable pancreatic adenocarcinoma.
For patients with borderline resectable pancreatic cancer, neo-
adjuvant therapy enjoys a more widespread consensus. It is
notable that of the 52 borderline patients, four were found to have
indeterminate or suspicious lung nodules on chest CT, all had
negative PET scans, and all four failed to show progression in the
lungs following neoadjuvant chemotherapy and surgery. Chest CT
demonstrated an unsuspected mediastinal mass (unrelated to
pancreas cancer) in one of the 52 patients with borderline resect-
able disease. These data would suggest that additional imaging
studies prior to the initiation of systemic therapy in patients with
borderline resectable disease will not identify clinically significant
disease that alters the management of this subgroup of patients.
In patients with localized pancreatic cancer, lung metastases
rarely occur in the absence of other contraindications for surgical
resection (other sites of distant disease or locally advanced
primary disease).8 Although the roles of chest CT and PET are well
established in the staging of other solid tumours, their roles in the
staging of periampullary cancer have not been fully evaluated.12–14
The only apparent benefit identified in the present study referred
to stage III disease, in which PET scanning identified extrapancre-
atic disease in two (8%) of 26 patients. These findings are similar
to data published previously by Nordback et al., who found a
benefit of routine chest CT imaging prior to the initiation of
anti-cancer therapy.8 In fact, only three (6%) of 53 patients had
lung metastases. Nordback et al. found no patients in whom treat-
ment sequencing was changed as all patients had imaging findings
which precluded surgical resection of the pancreatic cancer.8 In
the present report, only four (2%) of 247 patients had apparent
isolated lung metastases, but, interestingly, these were readily
identifiable on both the chest X-ray and the lower lung fields of
the abdominal CT. The additional staging benefit to routine chest
CT and PET scanning, in this study, appears to be negligible.
Patients with indeterminate pulmonary nodules, as defined in
this report, may not need further evaluation prior to treatment
when the initial treatment is systemic chemotherapy. It is not
routine practice at the present study centre to biopsy such lung
lesions found at the time of initial staging workup if neoadjuvant
systemic therapy is planned. Although a positive lung biopsy (for
adenocarcinoma of pancreatic origin) would change the stage of
disease (to stage IV) in patients with localized pancreatic cancer, it
would alter patient management only if a surgery-first treatment
strategy was planned. Therefore, this centre typically follows such
indeterminate or suspicious abnormal chest CT findings with
serial imaging, especially in patients with borderline resectable
disease (Katz types A, B or C). This treatment paradigm prevents
any delay in the initiation of treatment and avoids the potential
morbidities associated with lung biopsy and procedure-related
complications. In fact, in two instances, the performance of lung
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biopsies delayed the initiation of systemic therapy and both biop-
sies were non-diagnostic.
Further study may be necessary to make a firm recommenda-
tion on the utility of screening chest CT and PET in all patients
with pancreatic adenocarcinoma. It will also be important to
study the clinical significance of isolated lung metastases as sys-
temic therapies improve. Clinical observation suggests that lung
metastases are often somewhat indolent and certainly much less
aggressive than liver or peritoneal metastases. At present, this
group supports the use of high-quality abdominal CT imaging as
the cornerstone of initial staging and follow-up in patients with
pancreatic cancer.
In conclusion, the addition of chest CT and PET to abdominal
CT is of limited clinical utility; additional sites of metastasis are
rarely found. However, these data were acquired at an institution
which performs very high-quality abdominal imaging (to include
the lower lung fields); as the quality of abdominal imaging
declines, the yield from other imaging modalities will increase.
Dedicated pancreas-specific abdominal CT remains the corner-





1. Edge SB, Compton CC. (2010) The American Joint Committee on
Cancer: the 7th edition of the AJCC cancer staging manual and the future
of TNM. Ann Surg Oncol 17:1471–1474.
2. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd,
Casper ES et al. (2012) Pancreatic adenocarcinoma, version 2.2012: fea-
tured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703–
713.
3. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB et al.
(2008) Borderline resectable pancreatic cancer: the importance of this
emerging stage of disease. J Am Coll Surg 206:833–846; discussion
846–848.
4. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW.
(2009) Combined modality treatment of resectable and borderline resect-
able pancreas cancer: expert consensus statement. Ann Surg Oncol
16:1751–1756.
5. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick
RD. (2009) Surgical treatment of resectable and borderline resectable
pancreas cancer: expert consensus statement. Ann Surg Oncol 16:1736–
1744.
6. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang
H et al. (2006) Borderline resectable pancreatic cancer: definitions, man-
agement, and role of preoperative therapy. Ann Surg Oncol 13:1035–
1046.
7. Spiro SG, Porter JC. (2002) Lung cancer – where are we today? Current
advances in staging and non-surgical treatment. Am J Respir Crit Care
Med 166:1166–1196.
8. Nordback I, Saaristo R, Piironen A, Sand J. (2004) Chest computed
tomography in the staging of pancreatic and periampullary carcinoma.
Scand J Gastroenterol 39:81–86.
9. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT et al.
(2008) PET/CT fusion scan enhances CT staging in patients with pancre-
atic neoplasms. Ann Surg Oncol 15:2465–2471.
10. Kauhanen SP, Komar G, Seppanen MP, Dean KI, Minn HR, Kajander SA
et al. (2009) A prospective diagnostic accuracy study of 18F-
fluorodeoxyglucose positron emission tomography/computed tomogra-
phy, multidetector row computed tomography, and magnetic resonance
imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg
250:957–963.
11. Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pes-
talozzi BC et al. (2005) Positron emission tomography/computed tomog-
raphy influences on the management of resectable pancreatic cancer
and its cost-effectiveness. Ann Surg 242:235–243.
12. Borg MF, Benjamin CS, Childs WJ. (1993) The value of routine computed
tomography scanning of the chest in patients presenting with supradia-
phragmatic Hodgkin's disease. Australas Radiol 37:244–248.
13. White PM, Adamson DJ, Howard GC, Wright AR. (1999) Imaging of the
thorax in the management of germ cell testicular tumours. Clin Radiol
54:207–211.
14. Fleming JB, Cantor SB, Varma DG, Holst D, Feig BW, Hunt KK et al.
(2001) Utility of chest computed tomography for staging in patients with
T1 extremity soft tissue sarcomas. Cancer 92:863–868.
74 HPB
HPB 2014, 16, 70–74 © 2013 International Hepato-Pancreato-Biliary Association
